Conjugation of various serotypes of pneumococcal polysaccharide (PnPS
Streptococcus pneumoniae remains a significant pathogen in children under the age of two, splenectomized individuals, and the elderly, despite the availability of a purified multivalent S. pneumoniae capsular polysaccharide (PnPS) vaccine (2, 5, 14, 22) . Immunization with bacterial polysaccharide (PS) antigens typically induces a T-cell-independent type 2 antibody response characterized by high levels of immunoglobulin M (IgM), IgG antibodies primarily of the IgG 3 subclass in mice and IgG 2 in humans, an absent or blunted memory response, and no requirement for the direct involvement of T cells (16, 19, 20, 23, 24) . Polysaccharides are thought to be unable to bind to class II major histocompatibility complex (MHC), and are thus poor inducers of T-cell responses (12, 13, 16, 23, 24) . To overcome this limitation and to enhance immunogenicity, PSs have been conjugated to carrier proteins to make conjugate vaccines, an approach first reported in the 1920s and 1930s (3, 4, 9, 10) . This strategy has been highly successful in the prevention of infection with Haemophilus influenzae type b (Hib) (1, 21) .
While immunity to Hib requires antibodies to only one capsular PS serotype, there are at least 90 different S. pneumoniae capsular serotypes, more than 20 of which are considered clinically relevant (2) . Therefore, pneumococcal conjugate vaccines will require multiple conjugates, each consisting of a different PnPS linked to a carrier protein. However, clinical trials with a heptavalent PnPS-protein conjugate vaccine, in which each PnPS was conjugated to the same carrier protein, showed that the monovalent components of the vaccine had widely varying abilities to elicit PnPS-specific antibodies (5, 7, 17) . The reasons for such differences in immunogenicity are unclear, especially in instances where different PnPSs are attached by identical methods of conjugation to the same carrier protein.
In this report, we examine the immunogenicities of three PnPS-protein conjugate vaccines in a mouse model and investigate the mechanisms that might account for the significant differences observed in the magnitudes of PnPS-specific antibody responses despite linkage to the same carrier protein, Cross Reactive Material 197 (CRM 197 ) (25) . In particular, we address the hypothesis that conjugation of different PnPSs to a carrier protein such as CRM 197 can change the T-cell response to the conjugate vaccine by altering the antigen processing of the carrier protein, thereby modifying T-cell help for B-cell production of PS-specific antibodies. S. pneumoniae capsular serotypes 6B, 19F, and 23F were chosen for study due to the high clinical incidence of disease caused by these three serotypes in humans and because of their inclusion as components in the new heptavalent pneumococcal conjugate vaccine undergoing clinical trials (7, 17) . Our data show that conjugation of different PnPSs to the same carrier protein can alter the peptide specificity of T-cell responses. However, despite marked differences in the immunogenicity of the PnPS components of these pneumococcal conjugate vaccines in a mouse model, vigorous carrier protein-specific T-cell activation after immunization can be demonstrated with all three vaccines. (8) . These experimental lots did not contain any adjuvant, as is the case with the commercially available Hib-CRM 197 conjugate vaccine HibTITER. Unconjugated 6B, 19F, and 23F PnPSs were obtained from American Type Culture Collection (Rockville, Md.). These PnPS preparations are similar to those used in the conjugation procedure. Pneumococcal cell wall polysaccharide (C-PS) was obtained from the University of Rochester (Rochester, N.Y.). A series of peptides with an overlap of 12 amino acids was produced by multipin synthesis (Chiron Technologies, Raleigh, N.C.). All conjugates and unconjugated PnPS, CRM 197 , and peptides were determined to contain less than 0.1 U of endotoxin per ml of sample by using a Limulus amebocyte lysate assay (BioWhittaker, Walkersville, Md.).
MATERIALS AND METHODS

Antigens
Immunization of mice. Six-week-old female CBA/J mice (Jackson Laboratories, Bar Harbor, Maine) were immunized intraperitoneally (i.p.) on days 0 and 14 with 11 g (protein content) of CRM 197 , 10 g (PS content) of 6B-CRM 197 , 19F-CRM 197 , and 23F-CRM 197 , or 10 g of 6B, 19F, or 23F unconjugated PnPS in phosphate-buffered saline (PBS). The dose of unconjugated CRM 197 was approximately equivalent to the amount of CRM 197 injected into the conjugateimmunized mice. Ten micrograms of PnPS was chosen as the amount to be injected since dose response experiments demonstrated this dose to yield optimal antibody titers. Mice immunized with sterile PBS served as negative controls. CBA/J mice were chosen based on the availability of reagents for studying murine antigen processing and T cells, specifically the H-2 k system (11), and as a result of the observed differences in the immunogenicities of the different serotypes of pneumococcal conjugate vaccines. These differences in PnPS immunogenicity are similar to those observed in humans (17) . Mice were bled from the tail vein weekly for 5 weeks, and the sera were screened for anti-PnPS antibodies via enzyme-linked immunosorbent assay (ELISA) as described below.
ELISA for antibodies against polysaccharides and carrier protein. Ninety-sixwell PolySorp plates (Nunc, Roskilde, Denmark) were coated with 100 l of 6B, 19F, or 23F PnPS (obtained from the American Type Culture Collection) at 10 g/ml of PBS. These plates were previously found to bind all of these PnPS serotypes (26) . After plates were blocked with 200 l of PBS containing 1% bovine serum albumin and 1% NaN 3 , a 100-l sample was added to each well. Sera, standards, and controls were diluted in PBS containing 1% bovine serum albumin and 1% NaN 3 . Fifty micrograms of C-PS/ml of sera was added to absorb anti-C-PS antibodies (15) . Serum samples diluted 1:100 were used to assess relative differences in antibody production over time. To detect CRM 197 -specific antibodies, 96-well high-binding plates (Corning Glass Works, Corning, N.Y.) were coated with 100 l of a solution containing 1 g of CRM 197 per ml of a coating buffer (0.015 M Na 2 CO 3 , 0.035 M NaHCO 3 , pH 9.6). Serum samples were prepared as for the PnPS ELISA, except that C-PS was not added. The relative titers of IgM and IgG 1 PS-or CRM 197 -specific antibodies were determined for serum samples obtained 2 weeks after the secondary immunization. Serial dilutions of these sera were used in the ELISA. Antisera derived after hyperimmunization of BALB/c mice with 6B-CRM 197 , 19F-CRM 197 , or 23F-CRM 197 in monophosphoryl lipid-A (RibiImmunoChem Research, Hamilton, Mont.) served as positive controls. Detection of total PnPS-or CRM 197 -specific serum antibodies was performed by using goat anti-mouse kappa antibodies conjugated to alkaline phosphatase (AP) (Southern Biotech, Birmingham, Ala.). Anti-kappa antibodies were chosen since the vast majority of murine PS-specific antibodies contain kappa light chains. Serum antibodies of specific isotypes were detected by using goat anti-mouse-IgG 1 -AP and -IgM-AP antibodies. The plates were washed and developed with p-nitrophenyl phosphate (Sigma, St. Louis, Mo.) as the substrate, and absorbances were read as optical densities at 410 nm.
Lymph node proliferation assay. Female CBA/J mice were immunized in the hind footpads with 100 l of antigen (CRM 197 Statistical methods. An analysis of variance was used to determine statistical differences between experimental groups in the lymph node proliferation assays. Differences within groups were analyzed by the use of the Tukey multiple comparison method. The threshold for statistical significance was taken as p Յ 0.05. (Fig. 1A and B) . In addition, the total 6B-and 19F-specific serum antibody levels elicited by the conjugates, but not by the unconjugated PnPS, rose significantly after secondary immunization, as expected. The PnPS-specific antibodies elicited by immunization with the conjugates were primarily of the IgM and IgG 1 isotypes, in contrast to the predominantly IgM antibodies elicited by the unconjugated PnPS ( Fig. 2A and B) . PnPS-specific IgG 3 was not detected in any of the sera tested.
RESULTS
Immunization with 6B-CRM
In comparison, mice immunized with either 23F or 23F-CRM 197 had very low serum titers of 23F-specific antibodies ( Fig. 1C and 2C ). 23F-specific antibodies were, however, detected in sera from BALB/c mice immunized with 23F-CRM 197 , demonstrating that the appropriate 23F PnPS B-cell epitopes were not destroyed by the conjugation process (data not shown). Finally, CBA/J mice immunized with the conjugates in CFA according to the protocol for the lymph node proliferation assays had antibody titers similar to those of mice immunized i.p. without adjuvant. This immunization protocol also elicited relatively low titers of 23F-specific antibodies (data not shown).
When mice were immunized simultaneously with both 19F-CRM 197 and 23F-CRM 197 , the levels of 23F-specific antibody were very low (Fig. 3B) . These same mice, however, produced significant levels of 19F-specific antibodies, including antibodies of the IgG 1 isotype, production of which generally indicates the presence of T-cell help (Fig. 3A and C) . Thus, despite the evidence of carrier-specific T-cell help, 23F-specific antibody levels remained very low.
In contrast to PnPS-specific antibody responses, carrier-specific (CRM 197 ) antibody responses were equivalent in sera from mice immunized with 6B-CRM 197 , 19F-CRM 197 , and 23F-CRM 197 (Fig. 1D) . The predominant isotype of the CRM 197 -specific antibodies, following two immunizations, was IgG 1 (Fig. 2D) . These results indicate that an immunogenic form of CRM 197 was administered to all of the mice, that CRM 197 was processed and presented by antigen-presenting cells, and that T-cell help was elicited after immunization with any of the three conjugate vaccines used.
Conjugation of different PnPSs to CRM 197 yields similar magnitudes of lymph node cell proliferation upon restimulation in vitro. To more directly determine whether the serotypespecific difference in the ability to elicit PnPS-specific antibodies could be due to differential T-cell (18) . Cells from mice primed with 6B-CRM 197 proliferated more in response to the conjugates than in response to CRM 197 alone (p Յ 0.0011). Although CRM 197 was less effective at eliciting T-cell proliferation after immunization with 19F-CRM 197 or 23F-CRM 197 , these differences did not reach statistical significance (Fig. 4A, B, C, and D) . In addition, the responses of (Fig. 5) 
DISCUSSION
PS-protein conjugate vaccines have the potential to dramatically decrease the incidence of infection with PS-encapsulated bacteria such as pneumococcus. The Hib vaccines, the prototypes of successful conjugate vaccines, have resulted in the virtual eradication of disease due to Hib in the United States and much of the developed world. However, the Hib conjugate vaccines require multiple doses to achieve protection, and are thus costly, precluding widespread usage in the developing world. More detailed information on the properties of conjugate vaccines that contribute to greater immunogenicity may lead to improved designs for future conjugate vaccines.
Current hypotheses as to the mechanism by which the carrier protein enhances PS-specific immunogenicity envision internalization of the PS-carrier complex by the PS-specific B cells and proteolysis of the carrier protein, providing peptides able to bind noncovalently to class II MHC. The carrier confers on the PS-specific B cell the ability to activate helper T cells through the presentation of carrier-derived, class II MHC-bound peptides. The carrier-dependent boost to PSspecific immunogenicity is thus attributed primarily to carrierdependent T-cell help. It was thus assumed that linking different PnPSs to the same immunogenic carrier protein would comparably enhance PS-specific antibody titers.
Given the success of the Hib vaccine, it would seem straightforward to create a series of PnPS-protein conjugate vaccines that consist of capsular PS from common pathogenic serotypes conjugated to the same carrier proteins successfully used in Hib conjugates. In fact, recent clinical trials with a heptavalent vaccine, using CRM 197 as the carrier protein, showed clinical efficacy in preventing invasive pneumococcal disease from vaccine serotypes in children (7) . However, it is intriguing that in clinical studies significant variations in immunogenicity of the serotype-specific PnPS components of these vaccines utilizing the same carrier protein have been observed (17) . In the present study, we also observed pronounced differences in immunogenicity, in that the 23F-CRM 197 conjugate vaccine elicited substantially less PnPS-specific antibody than the 6B-CRM vaccines in CBA/J mice. Thus, while these mice were perfectly capable of making antibodies to two of the PnPSs, one PnPS serotype was a poor immunogen even when conjugated to the same immunogenic carrier protein. We chose to explore the possibility that variation in T-cell responses to the carrier protein caused by conjugation to a PS of different structure yielded differences in antigen processing that might account for the difference in PS-specific conjugate immunogenicity. Therefore, we immunized mice with the three conjugate vaccines or carrier alone and determined the reactivity of lymph node cells following restimulation in vitro with each of the conjugates or with carrier protein. Lymph node cells from mice immunized with any of the conjugate vaccines, including 23F-CRM 197 , proliferated similarly upon restimulation with any of the conjugates. A vigorous T-cell recall response was obtained even when the PnPS-specific antibody response was poor. Thus, these results do not provide evidence for a defect in the ability to activate carrier protein-specific T cells uniquely associated with the 23F-CRM 197 conjugate as an explanation for the observed deficiency in 23F PnPS-specific immunogenicity.
Lymph node cells from mice immunized with 6B-CRM 197 proliferated significantly more upon restimulation with conjugates than when stimulated with carrier alone, suggesting that antigen processing of the carrier protein linked to 6B PnPS yielded more peptide-MHC II complexes than were generated from the unconjugated carrier protein. 197 is not site specific, and the 23F PnPS may be bound to CRM 197 so as to change the patterns of proteolysis during processing, yielding presentation of a different set of epitopes than the other two pneumococcal conjugate vaccines containing structurally distinct PnPS. Since the 23F PnPS conjugate exhibits the lowest PS-specific immunogenicity, it is possible that 23F-CRM 197 elicited T cells that were not optimal for stimulation of 23F PnPS-specific B cells. However, the ability of 23F-CRM 197 to elicit a strong CRM 197 -specific antibody response as well as strong lymph node cell recall proliferative responses to the whole vaccines suggests that the 23F-CRM 197 vaccine activated helper T cells comparably to 19F-CRM 197 and 6B-CRM 197 .
Measurement of the antibody responses to the carrier protein following immunization with PnPS-CRM 197 conjugates indicated that all three PnPS conjugate vaccines elicited approximately equivalent amounts of total carrier-specific antibody and carrier-specific IgG 1 antibody. These results imply that the failure of the 23F conjugate to induce PnPS-specific antibody or PnPS-specific IgG in this model was not due to failures of antigen administration or antigenic integrity of the carrier protein unique to that conjugate. Furthermore, since the response to the carrier protein is T cell dependent, as supported by the significant production of carrier-specific IgG 1 , these results suggest that the carrier in the 23F conjugate was competent to induce helper T cells. Thus, simple measurement of antibody or T-cell responses to carrier proteins of CRM197  50  50  0  40  41  36  56  23  18  6B-CRM197  81  40  10  81  0  73  19  38  3  19F-CRM197  92  36  14  73  8  92  0  38  3  23F-CRM197  41  23  27  38  43  38  54 conjugate vaccines may not predict the immunogenicity of the PS.
In conclusion, our results suggest that variations in carrierinduced T-cell help may contribute to differences in the PSspecific immunogenicity of conjugate vaccines. However, the similarities in lymph node proliferation and CRM 197 immunogenicity between all the conjugates studied suggest that other mechanisms may also explain the poor immunogenicity of the 23F PnPS conjugate vaccine. Differences in PnPS-specific Bcell precursor frequency or PnPS-CRM 197 -induced patterns of cytokine production could contribute to the observed variation in the PnPS-specific immunogenicity of PnPS-CRM 197 conjugate vaccines.
